MedTrace Logo

CNS and Plasma Amyloid-Beta Kinetics in Alzheimer's Disease

NCT02021682 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 58

Last updated 2017-12-05

No results posted yet for this study

Summary

Alzheimer's disease (AD) is the most common cause of dementia and currently has no disease modifying treatments or simple accurate diagnostic tests. The goal of this project is to study how amyloid-beta (a protein thought to cause AD) is made, transported and cleared in the human body. Better understanding of these processes may lead to improved understanding of AD, earlier diagnosis and a way to evaluate treatment.

Conditions

Sponsors & Collaborators

  • National Institute of Neurological Disorders and Stroke (NINDS)

    collaborator NIH

  • Washington University School of Medicine

    lead OTHER

Principal Investigators

  • Randall J Bateman, MD · Washington University School of Medicine

Eligibility

Min Age
60 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-12-31
Primary Completion
2017-07-31
Completion
2017-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02021682 on ClinicalTrials.gov